Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) will be releasing its earnings data after the market closes on Wednesday, November 13th. Analysts expect Taysha Gene Therapies to post earnings of ($0.08) per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The business had revenue of $1.11 million during the quarter, compared to analysts' expectations of $3.62 million. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. During the same quarter in the previous year, the firm earned ($0.38) EPS. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA traded up $0.05 during midday trading on Thursday, reaching $1.42. 4,493,797 shares of the company's stock were exchanged, compared to its average volume of 2,406,366. Taysha Gene Therapies has a 12 month low of $1.19 and a 12 month high of $4.32. The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.22 and a current ratio of 5.22. The firm has a market capitalization of $291.02 million, a PE ratio of -7.18 and a beta of 0.44. The company's 50 day simple moving average is $2.01 and its two-hundred day simple moving average is $2.41.

Analyst Ratings Changes

TSHA has been the subject of a number of recent analyst reports. Needham & Company LLC lowered their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a "buy" rating for the company in a research report on Monday, August 12th. Chardan Capital reissued a "buy" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, August 13th. Finally, Canaccord Genuity Group cut their price target on Taysha Gene Therapies from $7.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday, August 14th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $6.38.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.